Lipid Management

Lp(a): The Genetic Cardiovascular Risk Factor Most People Have Never Heard Of

A risk factor that standard lipid panels do not measure, that diet and exercise cannot change, and that roughly 1 in 5 people carry.

Written by the ArterAI team · Last reviewed April 2026

This content is for informational purposes only and does not constitute medical advice. Always consult your physician regarding your individual health decisions.

There is a gap in standard cardiovascular screening. A lipid panel measures LDL, HDL, triglycerides, and total cholesterol. For most people, those numbers give a reasonable picture of risk. But they miss something — an independent, genetically determined risk factor that affects roughly 20% of the population and does not respond to any of the usual interventions.

That risk factor is lipoprotein(a), written as Lp(a) and pronounced “L-P-little-a.” It is an LDL-like particle with an extra protein — apolipoprotein(a) — tethered to it. Your Lp(a) level is almost entirely determined by the LPA gene. Unlike LDL or triglycerides, which can swing 20-30% based on what you ate last month, Lp(a) is set at birth and remains largely stable for life.

Why Lp(a) Matters

Lp(a) particles do two things that make them particularly dangerous. First, they deposit cholesterol in artery walls the same way LDL particles do. Second, the apolipoprotein(a) component is structurally similar to plasminogen — a protein involved in dissolving blood clots — and competes with it. The result is a particle that promotes both plaque formation and clot formation. That dual mechanism makes Lp(a) an independent risk factor: it increases cardiovascular risk even when LDL, HDL, and triglycerides all look normal.

What the data shows:

  • • Levels above 50 mg/dL (or 125 nmol/L) significantly increase cardiovascular risk — roughly 1.5-2x, independent of other lipid levels
  • • Elevated Lp(a) is associated with increased risk of heart attack, stroke, and calcific aortic valve stenosis
  • • Risk is multiplicative, not additive: high Lp(a) combined with high LDL, smoking, diabetes, or hypertension does not simply add risk — it compounds it

The Screening Problem

Standard lipid panels do not include Lp(a). This means someone can get perfect-looking bloodwork for 20 years while carrying a significant genetic risk factor that was never measured. The European Atherosclerosis Society now recommends universal Lp(a) screening — every adult, at least once in their lifetime. American cardiology guidelines are moving in the same direction, though adoption has been slower.

The rationale is straightforward. Lp(a) is common (roughly 1 in 5 people have elevated levels). It is hidden by default (standard panels do not measure it). It is stable (one test is good for life since the level is genetically determined). And knowing your level changes clinical decision-making, because it affects how aggressively your doctor should manage your other risk factors.

How Lp(a) Differs from LDL

This is the distinction that trips people up. LDL-C is highly modifiable: lifestyle changes can reduce it by 5-15%, statins by 30-50%, PCSK9 inhibitors by an additional 50-60% on top of statins. It responds to what you eat, how much you exercise, what medications you take.

Lp(a) does not respond meaningfully to any of those inputs. Diet does not move it. Exercise does not move it. Statins do not lower it — and may actually increase Lp(a) slightly in some patients, though the net cardiovascular benefit of statins still strongly favors taking them. PCSK9 inhibitors reduce Lp(a) by about 20-30%, which is helpful but modest compared to their LDL impact.

This is not a limitation of effort. It is a limitation of biology. Lp(a) production is governed almost entirely by the LPA gene, and until recently there were no therapies that could meaningfully intervene at that level.

What You Can Actually Do About Elevated Lp(a)

The fact that Lp(a) itself is not easily modifiable does not mean knowing your level is pointless. It changes your strategy.

Manage everything else harder

When you carry a non-modifiable risk factor, reducing every modifiable one becomes proportionally more important. Elevated Lp(a) is the reason some cardiologists push for an LDL target of 70 mg/dL or lower in patients who would otherwise be considered “borderline.” It is the reason to be more aggressive about blood pressure control, more serious about not smoking, more diligent about metabolic health.

Existing medications that partially help

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by about 20-30%. Niacin can reduce Lp(a) by 15-25%, though its side effect profile limits its use. Neither was designed to target Lp(a) specifically, and neither produces the kind of reduction that would bring a very high Lp(a) into the normal range. Your doctor can weigh whether these are worth considering based on your overall risk profile.

The treatment pipeline: what is coming

This is where the field is moving fast. Two RNA-based therapies are in late-stage clinical trials that target Lp(a) directly at the gene-expression level:

  • Pelacarsen (Novartis/Ionis) — an antisense oligonucleotide (ASO) that targets the mRNA encoding apolipoprotein(a), reducing Lp(a) production by approximately 80% in phase 2 trials. The phase 3 HORIZON trial is evaluating whether that biochemical reduction translates to reduced cardiovascular events.
  • Lepodisiran (Eli Lilly) — a small interfering RNA (siRNA) that achieved near-complete Lp(a) suppression (up to 97% reduction) in phase 1 data, with effects lasting several months per dose. Phase 3 trials are underway.

These are not hypothetical. If the phase 3 outcomes data confirms what phase 2 biochemistry suggests, they could fundamentally change the management of elevated Lp(a) for millions of people. But outcomes data matters — the history of lipid-lowering drugs includes several that moved biomarkers without moving clinical endpoints (see: HDL-raising drugs), so cautious optimism is warranted.

What If Your Lp(a) Is Normal?

Good — that is one fewer variable working against you. A normal Lp(a) (below 30 mg/dL or 75 nmol/L) means this particular genetic risk factor is not contributing to your cardiovascular risk. You do not need to retest it; the result is stable for life.

But a normal Lp(a) does not make you immune to cardiovascular disease — it simply removes one input from the equation. Your LDL, ApoB, triglycerides, and HDL still matter. So do blood pressure, blood sugar, smoking status, activity level, and family history. A normal Lp(a) with an LDL of 180 mg/dL still needs attention.

The value of the test is not just in finding a problem. It is in ruling one out, so you and your doctor can calibrate how aggressively to pursue everything else.

Getting Tested

Lp(a) is a standard blood draw that can be added to your regular lipid panel. Most insurance covers it, particularly if you have a family history of cardiovascular disease or elevated cholesterol. The test does not require fasting, and since the result is genetically determined, you only need to do it once.

Results are reported in mg/dL or nmol/L (the two are not directly interchangeable — a common source of confusion). Elevated is generally defined as above 50 mg/dL or 125 nmol/L, though some labs use different thresholds.

The ask is simple: at your next blood draw, tell your doctor you would like Lp(a) included. If they push back, the European Atherosclerosis Society's universal screening recommendation is your evidence base.

Lp(a) is one piece of the cardiovascular risk picture — alongside LDL, HDL, triglycerides, and ApoB. For the roughly 80% of people whose Lp(a) is normal, knowing that removes an uncertainty. For the 20% whose Lp(a) is elevated, knowing that changes how everything else should be managed.

Either way, the information is worth having. One blood draw. One result. Lifelong relevance.